Repurposing the anti-allergic drug into a cardioprotective drug: Tranilast-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Tranilast, an anti-allergy drug increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 1/March/2020, 5.43 pm

Mechanistic insights into how Vitamin C/Ascorbic acid enhances immunity against bacterial infections: Ascorbic acid-based immune enhancement therapy: Ascorbic acid increases SOX2 expression, and promotes innate immunity against bacterial infection, via down-regulation of its target gene, 28/February/2020, 10.27 am
February 28, 2020
How to Use iTunes On Windows 10 64 bit PC For Free
March 5, 2020
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20+)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the anti-allergic drug into a cardioprotective drug: Tranilast-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Tranilast, an anti-allergy drug increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 1/March/2020, 5.43 pm


From the significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.


From research findings to Therapeutic opportunity: 

This study provides, for the first time, mechanistic insights into how Tranilast [(3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′)] could aid in heart regeneration and repair.

Tranilast (brand name: Rizaben,  Ao Te Min, Arenist, Garesirol, Hustigen, Krix, Lumios, Tramelas and others), by regulating the expression of its target genes, it could: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration (fig.1).  Thus, pharmacological formulations encompassingTranilast or its activators, either alone or in combination with other drugs,” may be used to promote cardiac dedifferentiation and regeneration.

This image has an empty alt attribute; its file name is T-770x578.jpg

Figure1. Mechanistic insights into how Tranilast could promote cardiac dedifferentiation and regeneration. Tranilast, by regulating the expression of its target genes, it could upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

This image has an empty alt attribute; its file name is Tranilast-promotes-Cardiomyocyte-dedifferentiation-and-proliferation-through-activation-of-Her2-770x578.jpg

Figure 2. Anti-asthmatic agent Tranilast promotes cardiac regeneration through induction of Her2/Erbb2

This image has an empty alt attribute; its file name is Tranilast-promotes-Cardiomyocyte-dedifferentiation-and-proliferation-through-activation-of-Her3-770x578.jpg

Figure 3. Intracardiac/Epicardial injection of Tranilast could promote cardiac regeneration through induction of Her2/Erbb2

This image has an empty alt attribute; its file name is Tranilast-promotes-Cardiomyocyte-dedifferentiation-and-proliferation-through-activation-of-Her4-770x578.jpg

Figure 4. While it had been shown that  genetic ablation or pharmacological action of of Her2/ERBB2 inhibits cardiomyocyte proliferation and promotes dedifferentiation and proliferation followed by redifferentiation and regeneration, respectively, the study presented here suggests that injection or intake of Tranilast may promote cardiomyocyte proliferation and regeneration after myocardial infarction.

Given the mechanistic basis of how anti-allergic drug Tranilast [3′,4′-dimethoxycinnamoyl) anthranilic acid (N-5′)] or its analogs may aid in cardiomyocyte survival and regeneration,  medical practitioners and cardiologists may consider: (1) treating myocardial patients with Tranilast or its analogs(s), as it may aid in cardiomyocyte regeneration following myocardial infarction; and (2) putting into a clinical trial. 


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How does  Tranilast increase the expression of  ERBB2/Her2?

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Repurposing the anti-allergic drug into a cardioprotective drug: Tranilast-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Tranilast, an anti-allergy drug increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 1/March/2020, 5.43 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.